CRSP - CRISPR Therapeutics AG

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
46.37
+1.09 (+2.41%)
At close: 4:00PM EDT

46.49 +0.12 (0.26%)
After hours: 5:35PM EDT

Stock chart is not supported by your current browser
Previous Close45.28
Open45.78
Bid46.05 x 800
Ask46.47 x 900
Day's Range44.73 - 47.38
52 Week Range16.16 - 73.90
Volume957,195
Avg. Volume950,789
Market Cap2.384B
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-2.11
Earnings DateNov 6, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est66.93
Trade prices are not sourced from all markets
  • Here's Why CRISPR Therapeutics AG Fell as Much as 10.8% Today
    Motley Fool4 days ago

    Here's Why CRISPR Therapeutics AG Fell as Much as 10.8% Today

    The CRISPR gene editing pioneer announced a share offering to pad the balance sheet.

  • GlobeNewswire5 days ago

    CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares

    ZUG, Switzerland and CAMBRIDGE, Mass., Sept. 20, 2018-- CRISPR Therapeutics, a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced ...

  • Investor's Business Daily5 days ago

    Dow Jones Futures: Tilray, Marijuana Stocks Still Buzzing; Red Hat, Crispr Move On News

    Dow Jones futures: Tilray and other marijuana stocks were active Thursday after a wild Wednesday. Red Hat fell on weak sales and guidance. Crispr slid on a stock offering.

  • Benzinga5 days ago

    The Daily Biotech Pulse: Adverum Snags Fast Track Designation, Crispr To Offer Shares, Elanco Animal Health To Debut

    The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that struck 52-week highs on Sept. 19.) Acceleron Pharma Inc (NASDAQ: XLRN ...

  • CNBC6 days ago

    After-hours buzz: TLRY, RHT & more

    Tilray TLRY stock fell as much as 16 percent in after-hours trading, following a volatile trading day for the Canadian cannabis company. Shares closed up 38 percent, its best day ever as a public company, after surging as much as 90 percent during the day. The company also posted a strong run on Tuesday after the U.S. Drug Enforcement Administration gave the company the green light to import marijuana to the U.S. for medical research.

  • MarketWatch6 days ago

    Crispr stock down 5% after company plans secondary offer

    Shares of Crispr Therapeutics AG fell 5% in the extended session Wednesday after the gene-editing company said it plans to offer $200 million worth of shares of its common stock in a public offering. Underwriters will be granted a 30-day option to buy an additional $30 million, the company said in a statement. Goldman Sachs and Piper Jaffray are joint book-runners. Shares of Crispr ended the regular trading session down 2.4%.

  • GlobeNewswire6 days ago

    CRISPR Therapeutics Announces Proposed Public Offering of Common Shares

    CRISPR Therapeutics (CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced that it is commencing an underwritten public offering of $200,000,000 of its common shares. In addition, the underwriters will have a 30-day option to purchase up to $30,000,000 of additional common shares at the public offering price less the underwriting discount. Goldman Sachs & Co. LLC, Piper Jaffray & Co., Barclays Capital Inc. and Wells Fargo Securities, LLC are acting as joint book-running managers for the offering.

  • ACCESSWIRE6 days ago

    Stem Cell Deals Moving the Markets

    HENDERSON, NV / ACCESSWIRE / September 19, 2018 / The stem cell market has been very active recently, several stocks have been making deals and major breakthroughs. One stem cell play the market seems ...

  • GlobeNewswire9 days ago

    CRISPR Therapeutics and ViaCyte Announce Strategic Collaboration to Develop Gene-Edited Stem Cell-Derived Therapy for Diabetes

    -Aims to develop an immune-evasive stem cell therapy as a potentially curative treatment for diabetes-. -Parties will collaborate through commercialization and share costs and profits worldwide-. ZUG, ...

  • Is CRISPR Therapeutics AG a Buy?
    Motley Fool9 days ago

    Is CRISPR Therapeutics AG a Buy?

    On one hand, there's the promise of a groundbreaking technology. On the other hand, huge risk. Which hand wins?

  • Crispr Therapeutics Has Returned 130.62% Year-to-Date
    Market Realist11 days ago

    Crispr Therapeutics Has Returned 130.62% Year-to-Date

    Crispr Therapeutics (CRSP) has risen 130.62% YTD (year-to-date). This leading gene-editing company is focused on leveraging the CRISPR-Cas9 technology for developing therapies that target multiple hematology, immune-oncology, liver, and other organ-related indications.

  • A Financial Overview of Intellia Therapeutics in September
    Market Realist14 days ago

    A Financial Overview of Intellia Therapeutics in September

    In the second quarter, Intellia Therapeutics (NTLA) reported collaboration revenue of $7.7 million compared to $5.9 million in the second quarter of 2017. Intellia Therapeutics’ collaboration agreement with Regeneron Pharmaceuticals (REGN) primarily contributed to the increase in its collaboration revenue in the second quarter. In the first half of 2018, Intellia Therapeutics reported net collaboration revenue of $15.1 million compared to $12.1 million in the first half of 2017.

  • Analysts Are Mostly Positive on Intellia Therapeutics This Month
    Market Realist14 days ago

    Analysts Are Mostly Positive on Intellia Therapeutics This Month

    Intellia Therapeutics is a genome-editing company that’s currently focused on the development of curative therapies utilizing the CRISPR/Cas9 system. In August, Intellia Therapeutics presented data from a study in which a humanized mouse model of hereditary transthyretin amyloidosis demonstrated a reduction in amyloid deposition in multiple tissues after the administration of a single dose of lipid nanoparticles. Of the seven analysts tracking Intellia Therapeutics in September, three have recommended “strong buys,” while three have recommended “buys” on its stock.

  • A Financial Overview of Editas Medicine
    Market Realist15 days ago

    A Financial Overview of Editas Medicine

    In the second quarter, Editas Medicine (EDIT) reported revenues of $7.3 million from collaborations and other R&D (research and development) activities. In comparison, the company’s revenues reached $3.1 million in the second quarter of 2017.

  • GlobeNewswire15 days ago

    CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Provide Update on U.S Federal Circuit Decision Upholding the Ruling by U.S. Patent and Trademark Office in Interference Proceeding Relating to CRISPR/Cas9 Genome Editing Technology

    The interference proceeding remains terminated without any determination on inventorship of CRISPR/Cas9 genome editing application to eukaryotic cells University of California/University of Vienna/Dr. ...

  • Reuters15 days ago

    U.S. appeals court upholds MIT, Harvard patents on CRISPR gene editing

    The U.S. Court of Appeals for the Federal Circuit affirmed the validity of the Harvard and MIT patents, rejecting a challenge brought by a rival team of researchers associated with the University of California at Berkeley and University of Vienna in Austria. Shares of Cambridge, Massachusetts-based Editas Medicine Inc, a biotechnology company that licenses Harvard and MIT's CRISPR-related patents, rose nearly 7 percent after the ruling before giving back most of those gains and was up 1 percent at $30.56.

  • How CRISPR Therapeutics Is Positioned in September
    Market Realist15 days ago

    How CRISPR Therapeutics Is Positioned in September

    In the second quarter, CRISPR Therapeutics reported net income and EPS (earnings per share) of -$38.4 million and -$0.82, respectively, compared to net income and EPS of -$22.3 million and -$0.56 in the second quarter of 2017. In the first half of the year, CRISPR Therapeutics reported net income and EPS of -$66.7 million and -$1.44, respectively, compared to -$43.8 million and -$1.10 in the first half of 2017.

  • How Analysts View CRISPR Therapeutics in September
    Market Realist15 days ago

    How Analysts View CRISPR Therapeutics in September

    CRISPR Therapeutics (CRSP) has already obtained approval for clinical trial applications (or CTA) across multiple countries for its CTX001, an investigational autologous gene-edited hematopoietic stem cell therapy for the treatment of individuals with severe hemoglobinopathies. CRISPR Therapeutics and its partner, Vertex Pharmaceuticals, obtained CTA approvals for the evaluation of the therapy for the treatment of beta-thalassemia and sickle cell disease.

  • Better Buy: Editas Medicine, Inc. vs. CRISPR Therapeutics
    Motley Fool19 days ago

    Better Buy: Editas Medicine, Inc. vs. CRISPR Therapeutics

    Which stock wins in a one-on-one matchup between these two gene-editing biotechs?

  • Forget CRISPR Therapeutics: Vertex Pharmaceuticals Incorporated Is a Better Biotech Stock
    Motley Fool20 days ago

    Forget CRISPR Therapeutics: Vertex Pharmaceuticals Incorporated Is a Better Biotech Stock

    CRISPR Therapeutics might lead its start-up peers, but its collaboration partner is the better stock to buy.

  • Here's Why CRISPR Stocks Rose as Much as 18.7% in August
    Motley Fool21 days ago

    Here's Why CRISPR Stocks Rose as Much as 18.7% in August

    The three leading CRISPR gene-editing companies announced first-half 2018 earnings last month, and received a boost on the final day of August.

  • ACCESSWIRE22 days ago

    Today's Research Reports on Trending Tickers: CRISPR Therapeutics and Zogenix

    NEW YORK, NY / ACCESSWIRE / September 4, 2018 / Major U.S. equities closed mostly higher on Friday and posted upbeat performance for the week. Market volatility source have been coming from U.S. and international ...

  • 3 Biotech Stocks That Could Soar Next Week
    Motley Fool23 days ago

    3 Biotech Stocks That Could Soar Next Week

    Amarin Corporation, CRISPR Therapeutics, and Geron Corporation could all see big gains next week. Here's why.

  • About to Buy Penny Stocks? Look at These 3 Companies First
    Motley Fool25 days ago

    About to Buy Penny Stocks? Look at These 3 Companies First

    The allure of mega-returns can make penny stocks attractive. The reality is, this isn't where you'll find the next Apple or Amazon, and there is far more risk than potential reward. Here are three far better risk-reward investments to consider.

  • This Start-Up Thinks It Can Tackle One of CRISPR's Biggest Obstacles
    Motley Fool25 days ago

    This Start-Up Thinks It Can Tackle One of CRISPR's Biggest Obstacles

    CRISPR gene editing has endured a rough 2018 after years of hype. One start-up, which shares founders and tech with Editas Medicine, thinks it can move the field forward.